CI Investments Inc. Buys 19,633 Shares of Hims & Hers Health, Inc. $HIMS

CI Investments Inc. raised its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 9.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 226,145 shares of the company’s stock after buying an additional 19,633 shares during the period. CI Investments Inc. owned about 0.10% of Hims & Hers Health worth $4,695,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of HIMS. Norges Bank purchased a new position in shares of Hims & Hers Health during the fourth quarter worth approximately $62,153,000. Invesco Ltd. raised its stake in shares of Hims & Hers Health by 62.7% during the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after acquiring an additional 1,600,004 shares during the last quarter. Marex Group plc lifted its holdings in Hims & Hers Health by 162.2% in the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after buying an additional 1,496,707 shares during the period. Vanguard Group Inc. boosted its holdings in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares in the last quarter. Finally, Man Group plc boosted its stake in shares of Hims & Hers Health by 345.9% during the 2nd quarter. Man Group plc now owns 816,582 shares of the company’s stock valued at $40,707,000 after purchasing an additional 633,432 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total transaction of $830,410.00. Following the sale, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. This represents a 11.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 7,163 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87. Following the sale, the chief financial officer directly owned 284,321 shares in the company, valued at approximately $10,374,873.29. The trade was a 2.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 83,126 shares of company stock worth $2,711,339. Insiders own 11.76% of the company’s stock.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $32.67 on Friday. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $7.56 billion, a price-to-earnings ratio of -362.99, a PEG ratio of 89.16 and a beta of 2.35. The stock’s 50-day simple moving average is $30.69 and its 200-day simple moving average is $26.33.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm posted $0.20 EPS. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on HIMS shares. Citigroup lifted their price target on Hims & Hers Health from $28.00 to $35.00 and gave the company a “neutral” rating in a research report on Thursday. Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. reduced their price objective on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Barclays boosted their target price on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. Finally, Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $31.17.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.